Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In cancer immunotherapy, lipid-based nanoparticle (LNP) delivery systems encapsulated with mRNA for therapeutic CAR expression to reprogram T cells are gaining traction. Creative Biolabs is a contract research organization dedicated to the discovery and development of CAR therapies. We have world-class scientists, advanced technologies, and platforms to provide our clients with tailored solutions.
Generally, the CAR mRNA product was produced by in vitro transcription from a CAR IVT plasmid using the bacteriophage RNA polymerase. The structure of IVT mRNA is similar to endogenous mRNA, with five sections, from 5' to 3' is 5' cap, 5' untranslated region (UTR), an open reading frame that encodes the target genes, 3' UTR, and a poly(A) tail. Unlike retroviral typically used for CAR expression vectors, mRNA does not integrate into the genome, avoiding worries about insertional mutagenesis. IVT mRNA that encodes specific-targeted CAR genes can be translated into the cytoplasm without genomic integration, thus inducing transient CAR expression on cells. Additionally, IVT mRNA can be custom-built which allows it to be modified for improved transfection and translation.
LNPs commonly include an ionizable lipid, a PEGylated lipid, cholesterol, and a helper phospholipid, which together encapsulate and protect the mRNA core. These lipids remain neutral in a physiological pH, while in acidic buffer, ionizable lipids are positively charged and attract the RNA cargo to form nanoparticles. After LNP fusion with the endosomal membrane, ionizable lipids helped in endosomal escape and enable intracellular mRNA delivery.
Fig.1 Reprogram T cells in situ to express disease-specific CARs or TCRs using IVT mRNA carried by nanoparticles. (Parayath, 2020)
Creative Biolabs has years of experience in immunotherapy development. Our product development strategy is based on state-of-the-art technologies and instruments. A team of dedicated experts is well-positioned to develop, transfer and promote our client's project at any development phase. Creative Biolabs provides a comprehensive range of customized, high-quality CAR IVT plasmid, mRNA, as well as LNP products.
Creative Biolabs is dedicated to providing high-quality products in a timely and confidential manner. We want to work closely with our clients to build long-term, mutually beneficial relationships. We are delighted to assist you all the way from your scientific concept to pre-clinical studies. Our scientists are always there to help you succeed. We can also provide a comprehensive range of customized, high-quality CAR IVT plasmid, mRNA, as well as LNP products. Please contact us if you want to learn more.
Reference
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
